16.11.2012 • News • Kolb • chemical industry • chemicals

Kolb Expands Production in Moerdijk

A fourth reactor for the production of alkoxylates has been commissioned at chemical company Kolb's Dutch site in Moerdijk. As a result, Kolb Moerdijk is one of the biggest sites producing alkoxylates and non-ionic surfactants in Europe.

In addition, four new storage tanks have been constructed. This will enable a significant increase in the supply of fatty alcohols into Europe from its Malaysia-based parent company KLK.

The expansion has created 10 new jobs, increasing the total number of employees at the site to 80.

The expansion of production in Moerdijk is one of Kolb's biggest projects in recent years. In 2008, the capacity was expanded with a third reactor.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.